MedTrace Logo

A Study to Assess the Safety of ARGX-213 in Healthy Volunteers

NCT06968338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-04-23

No results posted yet for this study

Summary

This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body. The participants will remain in the study for approximately up to 21 weeks.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

ARGX-213

Intravenous or subcutaneous administrations of ARGX-213

OTHER

Placebo

Intravenous or subcutaneous administrations of placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-11
Primary Completion
2026-03-20
Completion
2026-03-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06968338 on ClinicalTrials.gov